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MeropenemAbstract Aim: The aim of this study was to compare the costs of management of moderate to sev-
ere infections in patients treated with imipenem/cilastatin (IC) and meropenem (MEM).
Pharmacoeconomic studies in Saudi Arabia are scarce. The current hospital formulary contains
2 carbapenems: IC and MEM. These antibiotics share a similar spectrum of activity. There are con-
ﬂicting reviews with regard to the relative cost-effectiveness of these two agents. Methods: A
retrospective, single-centre cohort study of 88 patients of IC versus MEM in moderate to severe
infections was performed, applying cost-minimization analysis (CMA) methods. In accordance with
CMA methods, the assumption of equivalent efﬁcacy was ﬁrst demonstrated by literature retrieved
and appraised. Adult patients (P18 years old) diagnosed with moderate to severe infections, includ-
ing skin and skin structure infections (SSIs), sepsis, intra-abdominal infections (IAIs), respiratory
tract infections, urinary tract infections (UTIs) and hospital-acquired infections (HAIs), who were
prescribed IC 500 mg every six hours intravenously (2 g per day) or MEM 1 g every eight hours (3 g
per day), were included in the study. Only direct costs related to the management of the infections
were included, in accordance with a payer perspective. Results: Overall there was no difference in
Cost-minimization analysis of imipenem/cilastatin versus meropenem 627the mean total daily costs between IC (SAR 4784.46, 95% CI 4140.68, 5428.24) and MEM (4390.14,
95% CI 3785.82, 4994.45; p= 0.37). A signiﬁcantly lower medicine acquisition cost per vial of IC
was observed when compared to MEM, however there was a signiﬁcantly higher cost attached to
administration sets used in the IC group than the MEM group. Consultation, nursing and physician
costs were not signiﬁcantly different between the groups. No differences were observed in costs
associated with adverse drug events (ADEs). Conclusion: This study has shown that while acquisi-
tion costs of IC at a dose of 500 mg q6 h may be lower than for MEM 1 g q8 h, mean total costs per
day were not signiﬁcantly different between IC and MEM, indicating that medicine costs are only a
small element of the overall costs of managing moderate to severe infections.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As in almost every health system, medication costs at the King
Abdulaziz Hospital (KAH) have increased noticeably over
time (Saggabi, 2012). High prices of essential medicines are a
heavy burden on the government budget (Saggabi, 2012).
Policymakers are thus in search of the most cost-effective
options for the government and society as a whole.
Data from KAH show that the carbapenem antibiotics
were the third most expensive pharmacological class procured
during 2009. The current hospital formulary lists two car-
bapenems: the ﬁxed-dose combination of imipenem/cilastatin
(IC) and meropenem (MEM). MEM is restricted to infection
control physicians, while IC is restricted to infection control,
intensivists and haematology/oncology practitioners. These
antibiotics share a similar spectrum of activity, but the unit
cost of IC (500 mg/500 mg) is less than that for the equipotent
dose of MEM (1 g). There are conﬂicting reviews with regard
to the relative cost-effectiveness of these two medicines
(Attanasio et al., 2000; Edwards et al., 2006).
An unpublished pharmacoeconomic review, at the Ministry
of National Guard Health Affairs, showed that an interchange
programme, substituting MEM with IC, would lead to a cost
saving of 2,306,257 Saudi Riyals (SARs) per year (614,309
US dollars per year). Hospital antimicrobial usage data since
2004 showed that usage of IC had been markedly lower than
the usage of MEM. There have been limited applications of
pharmacoeconomic evaluations in Saudi Arabia (Al Aqeel
and Al-Sultan, 2012). It would be appropriate, therefore, to
test the economic impact of the proposed substitution as well
as the main factors inﬂuencing hospital costs, in this setting,
based on pharmacoeconomic principles. In this regard, cost-
minimization analysis (CMA) could provide an estimate of
the economic impact of these therapeutically equivalent
medicines, using local Saudi Arabian data.
The aim of this study was to contribute to the rational
selection of medicines, in order to achieve efﬁciencies and bet-
ter patient outcomes, by focusing on high-cost medicines used
in the Saudi Arabian health system.
2. Background
In 2012, total annual expenditure on MEM at KAH placed
it in the top 10 medicines at the institution in value
terms. The Department of Infection Control, Department of
Microbiology and Pharmacy attempted to minimize usage of
MEM by suppressing mention of this agent in sensitivityreports appearing in the hospital’s electronic health informa-
tion system. This was implemented in an attempt to encourage
usage of alternative antibiotics, including IC. The Pharmacy
and Therapeutics Committee (PTC) also restricted the use of
MEM to infection control practitioners only. IC was restricted
to infection control, intensivists and haematology/oncology
practitioners. The Infection Control Department developed
usage guidelines for IC and MEM. An unpublished
pharmacoeconomic review examined the acquisition costs of
the study drugs, but did not include the resource costs
associated with the primary infection. A CMAwas therefore pro-
posed in an attempt to investigate the overall costs associated
with the use of these two clinically equivalent medicines.
2.1. Pharmacoeconomic principles
The ﬁeld of pharmacoeconomics identiﬁes the costs and conse-
quences of alternative medicines therapy in order to make the
best possible decision, while ensuring the maximum beneﬁt
and efﬁciency of budgets or resources (Drummond, 2006). In
this study, a CMA approach was selected, which assumes that
the consequences are clinically equivalent and then determines
the least costly alternative (Newby and Hill, 2003). Studies on
the local population may be more applicable to the context of
Saudi Arabia and hence a study of this nature was considered.
2.2. Pharmacology
IC and MEM are both carbapenem antibiotics. These beta-lac-
tam antibiotics are similar to penicillins and cephalosporins,
but differ in their structure. Carbapenems inhibit bacterial cell
wall synthesis. Both IC and MEM exhibit activity against a
wide range of Gram-positive and Gram-negative aerobic and
anaerobic bacteria.
The ﬁrst carbapenem (imipenem) became commercially
available in 1985 for the treatment of complex microbial infec-
tions (Papp-Wallace et al., 2011). The ﬁxed-dose combination
IC (including the dehydropeptidase inhibitor cilastatin) has
been marketed by Merck Sharp and Dome with the trade name
Tienam in Saudi Arabia (Anonymous, 2013). The United
States Food and Drug Administration (FDA) has approved
the dose of IC from between 250 mg q6 h to a maximum of
1 g q8 h, depending on the severity of the infection. The dose
should be adjusted in patients with impaired renal function.
MEM is a broad spectrum carbapenem, subsequently approved
by the US FDA (Mohr, 2008; Baldwin et al., 2008). It has been
marketed by AstraZeneca in Saudi Arabia as Meronem
628 I. Joosub et al.(Anonymous, 2013). The dose should be adjusted in patients
with compromised renal function (Merrem, 2006). The FDA-
approved MEM dosage for mild to severe infections varies
from 500 mg to 1 g every six to eight hours.
3. Literature review
In order to justify the CMA approach used in this study, a
literature review was ﬁrst conducted to justify the a priori
assumption of clinical equivalence of IC and MEM in the
types of infections treated and the doses recommended in the
KAH guidelines.
3.1. Literature search approach and methods
The sources used included the Cochrane Library, Medline
database, Trip database and Google Scholar. The search
terms employed included: efﬁcacy, safety, adverse reactions,
effectiveness, pharmacoeconomic, bacterial infections, skin
infections, sepsis, urinary tract infections, respiratory tract
infections, hospital-acquired infections, meropenem and
imipenem.
Randomised controlled trials (RCTs) were considered the
gold standard when comparing IC to MEM. However, system-
atic reviews, meta-analyses, pharmacoeconomic studies and
other review articles were also retrieved. Studies were critically
appraised for quality and relevance using the ‘‘Critical apprai-
sal skills programme, United Kingdom’’ tool (Singh, 2013),
where the full text could be retrieved.
Studies published in any language since the year 1995 were
considered, although only those provided in English or in
English translation could be included. The searches were last
updated in October 2013.Table 1 Summary of critical appraisal.
Critical appraisal ﬁndings Supported by
1 IC clinically equivalent to MEM in
patients with IAI
No diﬀerence in clinic
1998; Badia et al., 199
Colardyn and Faulkne
2 IC clinically equivalent to MEM in SSI No diﬀerence in clinica
et al., 2006; Fabian et
3 IC clinically equivalent to MEM in LRTI No diﬀerence in clinic
Xiao-Ju et al., 2001; X
4 IC clinically equivalent to MEM in UTI No diﬀerence in clinic
et al., 2002; Cox et al.
5 IC clinically equivalent to MEM in sepsis No diﬀerence in clinic
6 IC bacteriologically equivalent to MEM No diﬀerence in bacte
Geroulanos, 1995; Son
7 IC as safe as MEM No diﬀerence in adver
et al., 1999; Geroulano
et al., 2005; Nichols et
et al., 1995; Kuo et al
8 IC less costly than MEM IC less costly than ME
Badia et al., 1999; Bek
9 IC 500 mg q6 h and MEM 1 gram q8 h This dosage supported
2006) and our hospita
Key: IAI = intra-abdominal infection, SSI = skin and skin structure i
tract infection, IC = imipenem/cilastatin, and MEM=meropenem.3.2. Literature retrieved and appraised
A total of 28 relevant studies were retrieved, matching the
search criteria and applicable to the international context.
No studies conducted in Saudi Arabia could be found. The
search found two meta-analyses, one systematic review (with-
out meta-analysis), 12 RCTs, one prospective cohort study,
and one retrospective cohort study that supported the position
of clinical equivalence between IC and MEM. The six studies
that did not show clinical equivalence were a pharmacoeco-
nomic review, two systematic reviews and three RCTs. The
present study evaluated IC at a dose of 500 mg q6 h versus
MEM 1 gm q6 h. This dosage has been supported by the
KAH antimicrobial guidelines (MNGHA, 2012) as well as
the US FDA (Merrem, 2006; Primaxin, 2006). This choice is
also supported by a systematic review (Zhanel et al., 1998).
Some studies could not be reviewed in detail, either due to
being in a foreign language or where an unclear conclusion
was recorded.
The key ﬁndings of this appraisal provided convincing
evidence of the clinical equivalence of IC and MEM. These
ﬁndings are summarized in Table 1:4. Methods
4.1. Type of research
This study was a retrospective, single-centre cohort
employing CMA principles. The CMA assumes that
consequences are equivalent while seeking the least expensive
alternative (Dakin and Wordsworth, 2013; Walley and
Haycox, 1997).al eﬃcacy supported by studies (Attanasio et al., 2000; Zhanel et al.,
9; Zanetti et al., 1999; Geroulanos, 1995; Beketov et al., 2003;
r, 1996)
l eﬃcacy supported by studies (Colardyn and Faulkner, 1996; Embil
al., 2005; Nichols et al., 1995)
al eﬃcacy supported by studies (Colardyn and Faulkner, 1996;
iao et al., 2010; Song et al., 2001; Hou et al., 2002; Verwaest, 2000)
al eﬃcacy supported by studies (Colardyn and Faulkner, 1996; Hou
, 1995)
al eﬃcacy supported by studies (Verwaest, 2000; Kuo et al., 2000)
riological outcomes supported by studies (Attanasio et al., 2000;
g et al., 2001; Cox et al., 1995; Kuo et al., 2000)
se drug events supported by studies (Attanasio et al., 2000; Zanetti
s, 1995; Colardyn and Faulkner, 1996; Embil et al., 2006; Fabian
al., 1995; Xiao et al., 2010; Hou et al., 2002; Verwaest, 2000; Cox
., 2000; Hoﬀman et al., 2009)
M supported by studies (Attanasio et al., 2000; Zhanel et al., 1998;
etov et al., 2003)
by Zhanel et al. (1998), United states FDA (Merrem, 2006; Primaxin,
l Antimicrobial guidelines (MNGHA, 2012)
nfection, LRTI = lower respiratory tract infection, UTI = urinary
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A CMA of IC versus MEM in moderate to severe infections
was conducted at the KAH, Al-Ahsa (a 300 bed tertiary care
centre). Between January 2012 and December 2012, all
patients receiving IC 500 mg every six hours and MEM 1 g
every eight hours for moderate to severe infection were
included in the study. The study set out to capture 100 patient
ﬁles with 50 patients in each arm, based on the estimated cen-
sus of patients treated with these medicines in a calendar year.
The perspective of the economic evaluation was that of the
provider or payer, in this case the Ministry of National Guard
in Saudi Arabia that provides health-care to eligible
dependents.
4.3. Study population
The inclusion criteria applied were: adult patients (P18 years
old); patients diagnosed with moderate to severe infection,
including SSI, sepsis, IAI, respiratory tract infections, UTI
and HAI who were prescribed IC 500 mg every six hours intra-
venously (2 g per day); patients diagnosed with moderate to
severe infection, including SSI, sepsis, IAI, respiratory tract
infections, UTI and HAI who were prescribed MEM 1 g every
eight hours intravenously (3 g per day).
The exclusion criteria applied were: those that were preg-
nant; with known or suspected meningitis; diagnosed with
microorganisms resistant to IC or MEM; patients with a docu-
mented hypersensitivity or prior contraindication to IC or
MEM.
4.4. Data collection
Data on patients’ gender, age, weight, diagnosis, medical his-
tory, laboratory test results (including renal function and
haematological status), recorded comorbid illnesses and pre-
vious medicines allergies, prescribed antifungals or antibiotics
and microbiological tests were extracted from the hospital’s
electronic medical record. Information about consultant and
physician visits was extracted from the paper-based physician
notes, as were clariﬁcations of the recorded diagnosis in cases
where electronic records were incomplete. The documented
outcomes were the length of hospitalization, length of antibi-
otic stay (LOAS: deﬁned as the number of hospital days during
which the patient was being treated for the diagnosed infec-
tion, including any treatment associated with treatment failure
or related ADEs), and the resource consumption (limited to
direct medical costs of managing the primary infection, based
on the payer perspective).
4.5. Statistical analysis
The primary objective of the study was to compare the costs of
management of moderate to severe infections in patients trea-
ted with IC and MEM. Descriptive statistics were presented as
mean ± standard deviation for all continuous variables (e.g.,
age) while number (%) were reported for all categorical vari-
ables (e.g., gender). Bivariate analysis was performed by using
Independent Sample t-test or Mann Whitney U-test whenever
appropriate to compare the mean for all the continuousvariables (e.g., age) between two groups (IC vs. MEM).
Pearson Chi-Square test or Fisher exact test, as appropriate,
were used to compare the proportion for all the categorical
variables (e.g., gender) between the two groups. A two sided
p-value < 0.05 was considered statistically signiﬁcant. All sta-
tistical analyses were performed using SPSS (Statistical
Package for social sciences version 21).
4.6. Deﬁnitions
The diagnosis of moderate to severe infection, as described in
the inclusion criteria, was based on the treating physician’s
documented clinical decision. In the case that the diagnosis
was not clear, the patients’ medical record was used to conﬁrm
the primary infection. Clinical success was dependent on the
source of infection and deﬁned by clinical improvement in
signs and symptoms that would warrant resolution of fever
or clinical signs of infection, discontinuation of antibiotics or
discharge from the hospital without re-admission within
10 days or eradication of baseline positive microbiological
pathogens. Evidence of the outcomes in each case was docu-
mented by the attending physician in the clinical notes.
Adverse drug events (ADEs) associated with IC or MEM
were identiﬁed based on physician documentation and the
records extracted from the hospital information system. The
following circumstances were considered to be indicative of
an ADE associated with IC or MEM: seizures, skin reactions,
gastrointestinal disturbances, changes in liver function tests of
more than 3 times the upper normal limit and changes in renal
function (to a creatinine clearance less than 50 ml/min).
4.7. Costing
Pricing data were obtained from the ﬁnancial section of the
hospital’s business centre. National drug prices were obtained
from the Saudi Food and Drug Authority (SFDA) Human
Drug List (http://www.sfda.gov.sa). The prices used were those
in effect in October 2013. Direct medical costs included the
costs of medications, laboratory tests, health care provider
costs, hospitalization costs, consumables and administration
costs. Direct non-medical costs (transportation and food) were
not included in the study. Indirect medical costs (lost income)
and intangible costs (pain and suffering) were excluded as
incompatible with the perspective of the present study. Costs
associated with support personnel such as maintenance, house-
keeping, patient escort and administration were assumed to be
ﬁxed and were not included in the study. Laboratory data
unrelated to the primary infection or super infections were
not considered in the study. Investigators’ and data collectors’
fees were excluded. Discounting was not considered as the
study period was for a single year. Pricing was in Saudi riyals
(SARs). One SAR has been ﬁxed at approximately 0.27 United
States dollars (USD) for the last 10 years.
4.8. Pharmacoeconomic analysis
The perspective was that of the provider or payer, a govern-
ment institute. The study period began at the point the primary
infection was diagnosed. The LOAS was used to determine the
time period of the costing analysis.
Table 2 Baseline characteristics.
IC (n= 44) MEM (n = 44) P value
Age in years 65.64 ± 19.04 64.11 ± 21.28 0.724
Weight in kg 71.31 ± 15.81 68.80 ± 21.92 0.538
Height in cm 159.32 ± 11.15 157.82 ± 10.06 0.509
Male (%) 21 (47.73%) 20 (45.45%) 0.831
Results are expressed as mean ± standard deviation, and
number (%).
630 I. Joosub et al.One-way sensitivity analysis was performed, in Microsoft
Excel 2010, by increasing and decreasing each parameter by
20%, while observing the impact on the results. A threshold
analysis was performed, in Microsoft Excel using ‘what-if-
analysis’.
4.9. Ethics
The protocol received approval from the King Abdullah
International Medical Research Centre (reference number
RRE12/011) eastern region of Saudi Arabia, as well as the
Biomedical Research Ethics Committee at the University
of KwaZulu–Natal in South Africa (reference number BE:
273/13).
5. Results
Although it was planned to include 50 patients in each group
from 1 January 2012 until 31 December 2012, IC was pre-
scribed to only 45 patients on IC during this period. One ﬁle
could not be accessed as it was locked by the Health
Information Management Department. Only 44 patients on
MEM met the inclusion and exclusion criteria. In total, six
patients were excluded from the study, due to diagnosis with
meningitis (n= 1), pregnancy (n= 1), being under 18 years
of age (n= 1), ﬁles being locked (n= 2) and administration
of only a single dose (n= 1). A total of 44 patients receiving
IC and 44 receiving MEM could therefore be evaluated.
5.1. Baseline characteristics
Baseline characteristics are summarized in Table 2. There were
no signiﬁcant differences in baseline characteristics between
the groups.
5.2. Number of hospital days
There was a signiﬁcant greater number of mean critical care
days in the IC group compared to the MEM group
(p= 0.030). However, the mean number of step-down days
(p= 0.375), mean general ward (GW) days (p= 0.472) and
LOAS (p= 0.212) showed no signiﬁcant difference.Table 3 Clinical characteristics.
IC (n= 44)
Clinical success 26 (59.1%)
Peak temperature in C 37.98 ± 0.82
WBC 109 L 19.27 ± 10.89
Normal renal function 35 (79.5%)
Moderate renal impairment 9 (20.5%)
Number of positive skin infections 7 (15.9%)
Number of positive sepsis cases 13 (29.5%)
Number of positive IAIs 5 (11.4%)
Number of positive LRTIs 9 (20.5%)
Number of positive UTIs 21 (47.7%)
Number of positive HAIs 16 (36.4%)
Key: IC = imipenem/cilastatin; MEM=meropenem WBC= white b
respiratory tract infection; UTI = urinary tract infection; HAI = hosp
deviation, and number (%).5.3. Clinical characteristics
Clinical success rates and other clinical parameters are shown
in Table 3 and were not statistically different between IC and
MEM.
5.4. Adverse drug events (ADEs)
Gastrointestinal ADEs occurred in 1 (2.3%) of the patients on
IC and 3 (6.8%) of the patients on MEM. General ADEs
occurred in 1 (2.3%) patient on IC and 1 (2.3%) patient on
MEM. Laboratory ADEs occurred in 5 (11.4%) patients in
the IC group, compared with 6 (13.6%) patients in the
MEM group. One case of seizure associated with IC was
documented.
5.5. Hospital resources
Hospital resources showed no signiﬁcant difference in the
mean number of consultant visits (p= 0.088) and mean GW
nurse days (p= 0.642). The mean pharmacist time (in min)
was signiﬁcantly higher in the IC group compared to the
MEM group (p= 0.004) as well as the mean pharmacy aide
time (p= 0.004). The mean number of administration sets
used in the IC group was also signiﬁcantly higher than in the
MEM group (p= 0.001).
5.6. Economic evaluation
Resource utilization costs are listed in Table 4 as the mean
resource cost per day. Comparison of the mean daily costsMEM (n= 44) P value
28 (63.6%) 0.661
37.89 ± 0.78 0.597
22.57 ± 23.44 0.401
34 (77.3%) 0.796
10 (22.7%) 0.796
7 (15.9%) 0.99
16(36.4%) 0.496
3 (6.8%) 0.458
7 (15.9%) 0.580
22 (50.0) 0.831
9 (20.5%) 0.098
lood cell count; IAI = intra-abdominal infection; LRTI = lower
ital acquired infection. Results are expressed as mean ± standard
Table 4 Resource utilization costs.
Average daily costs IC mean MEM mean P value
CCU 1022.73 ± 706.73 784.09 ± 757.89 0.130
Step-down 572.73 ± 437.95 572.73 ± 437.95 0.99
GW 372.16 ± 218.16 465.91 ± 127.49 0.016
Vials 250.63 ± 41.34 393.48 ± 89.99 <0.001
Administration sets 39.16 ± 6.46 28.00 ± 4.57 <0.001
Laboratory tests 904.96 ± 810.29 761.32 ± 708.77 0.379
Laboratory cultures 86.61 ± 40.42 129.64 ± 105.78 0.014
CCU consult 681.82 ± 471.16 522.73 ± 505.26 0.13
GW consult 205.26 ± 297.77 200.47 ± 284.15 0.939
Staﬀ physician 264.48 ± 136.98 215.55 ± 96.39 0.056
CCU nurse 204.55 ± 141.35 156.82 ± 151.58 0.13
GW nurse 92.88 ± 25.49 93.18 ± 25.50 0.956
Pharmacist 64.08 ± 10.57 46.82 ± 10.71 <0.001
Pharmacy aide 21.36 ± 3.52 15.61 ± 3.57 <0.001
ADE 1.05 ± 3.48 3.78 ± 18.24 0.333
Totals 4784.46 ± 2117.50 4390.13 ± 1987.70 0.37
Key: IC = imipenem/cilastatin; MEM=meropenem; CCU= critical care unit; GW= general ward; ADE= adverse drug events. Results
are expressed as mean ± standard deviation.
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difference in terms of mean daily critical care unit (CCU) and
step-down costs. A signiﬁcant lower medicine acquisition
vial cost was observed for IC (SAR 250.63, 95% CI
238.06–263.20) compared to MEM (SAR 393.48, 95% CI
366.12–420.84) (p< 0.001). However there was a signiﬁcantly
higher cost attached to administration sets in the IC group
(SAR 39.16, 95% CI 37.2–41.13) than in the MEM group
(SAR 28.00, 95% CI 26.61–29.39) (p< 0.001).
Overall there was no difference in the mean total daily costs
between IC (SAR 4784.46, 95% CI 4140.68–5428.24) and
MEM (SAR 4390.13, 95% CI 3785.82–4994.45) (p= 0.37),
as shown in Table 4.
One-way sensitivity analysis showed that the parameters
which exerted the greatest change in the mean total cost were
the number of CCU days, laboratory tests and consultation
charges (as shown in Fig. 1).
The threshold analysis found that variations in the number
of ADEs, vial costs, administration costs and pharmacists’4,550 4,600 4,650 4,700 4,7
CCU days
GW days
Admin Sets
Lab. cultures
GW Consult
CCU Nurse
Pharmacist
ADE
Mean D
20% decrease
Figure 1 One way sensitivity analysis with IC (mean value = SAR
riyal; CCU= critical care unit; GW= general ward; ADE = adversecosts did not affect the conclusion even if the input value of
each of the acquisition costs parameter was set at SAR 0.00.
6. Discussion
Several factors prompted the need for a pharmacoeconomic
evaluation of IC and MEM. These included an institutional
review of antimicrobial restriction and concerns about usage
and costs. Most importantly, interchanging MEM with IC
was thought to be able to lead to a cost saving of more than
two million Saudi Riyals, as the acquisition costs of IC were
noted to be less than those for MEM (SAR70.4 versus SAR
151.26 per vial). In addition, published pharmacoeconomic
evaluations are limited in Saudi Arabia (Al Aqeel and
Al-Sultan, 2012). To our knowledge, no published
pharmacoeconomic evaluations comparing IC and MEM in
adult patients have been conducted in Saudi Arabia. There
have been several international pharmacoeconomic evalua-
tions done (Attanasio et al., 2000; Edwards et al., 2006;50 4,800 4,850 4,900 4,950 5,000
aily Cost (SAR)
20% increase
4784.46). Key: IC = imipenem/cilastatin; SAR= Saudi Arabian
drug events. Results are expressed as mean ± standard deviation.
632 I. Joosub et al.Badia et al., 1999), but with conﬂicting results. Using data
based on the local perspective therefore had the potential to
provide insight into the factors inﬂuencing local practice and
medicines selection. Government institutions in Saudi
Arabia, providing free medical treatment, may adopt similar
costing strategies that are unique to this region.
At a dose of 500 mg q6 h (cost = SAR 281.60 per day), IC
is an attractive alternative to MEM 1 gram q8 h (cost = SAR
453.78 per day), particularly in mild to moderate infections.
In the cohort of patients followed for this study, clinical
success rates were not signiﬁcantly different. The number of
positive infections appeared similar. LOAS was not sta-
tistically different in both groups. The clinical efﬁcacy data
cohort was therefore in agreement with the literature justifying
clinical equivalence.
The overall ADEs were not signiﬁcantly different between
the groups. It was found, though, that ADEs were under-re-
ported. Although more patients had gastrointestinal ADEs
in the MEM group, this was not signiﬁcantly different when
compared to IC. These were mainly antibiotic-associated diar-
rhoea, resulting in C. difﬁcile culture being taken. One patient
on IC experienced a seizure. Concern about this adverse effect
has prompted the avoidance of IC among health care workers
in our hospital. It must be pointed out that Hoffman et al.
found no difference in seizure rates between patients treated
with IC andMEM (Hoffman et al., 2009). These authors noted
that elderly patients, patients with low body weight, at risk of
CNS disease, those with a history of seizure and those with
renal dysfunction appear to be at increased risk of drug-related
seizures. On this basis, the patient in our cohort who developed
seizures was at increased risk. This study excluded patients
with bacterial meningitis, due to this population being at risk
for seizures. In addition, our hospital guidelines (MNGHA,
2012) do not advocate the use of IC in those at increased risk
of seizures and in patients with poor renal function. Our study,
in agreement with Hoffman et al. Hoffman et al. (2009) did not
show signiﬁcant differences in ADEs associated with IC or
MEM.
The number of physician and nursing visits were signiﬁ-
cantly higher in the IC group than the MEM group. This
was attributed to more CCU days in the IC group, which
necessitated more physician and nursing visits. As expected,
the mean pharmacists’ time (in min) was signiﬁcantly higher
in the IC group compared to the MEM group. The institute
prepares both antibiotics in the intravenous admixture room.
IC was given 4 times daily while MEM was given 3 times daily.
The delivery by the pharmacy aide showed more delivery time
with IC compared to MEM. For the same reason, more
administration sets and minibags were required for the IC
group. The results clearly demonstrate that signiﬁcantly more
time is required per day to prepare IC compared with MEM.
Overall, more hospital resources are required in the prepara-
tion, dispensing and administration of IC compared to MEM.
Total hospital days, especially the total CCU days, in the
IC group were signiﬁcantly higher. The longer CCU days were
believed to inﬂuence costing, especially in the IC group.
Patients varied signiﬁcantly in regard to the number of CCU
days. Independent sample t-tests showed no signiﬁcant differ-
ence in terms of mean daily hospital costs and step-down costs.
However the GW costs in the IC group was signiﬁcantly lower
in the IC group compared to MEM (p= 0.016). Although
total CCU costs were higher, cost per day was not statisticallydifferent between the two groups, except in terms of the GW
days. More patients in the MEM group spent a greater number
of days in the GW unit, which drove up mean costs in this
group.
The mean total daily costs of vials in the IC group were
much lower than in the MEM group (SAR 250.63 vs.
393.48). This was expected, as the cost of IC, given 4 times
daily, would result in daily costs of SAR 281.60 versus
MEM, given 3 times daily, at SAR 453.78. The mean costs
in our study were mean costs reﬂecting dose changes as well.
In the institution, a previous unpublished study showed that
this difference in acquisition costs could result in a savings
of more than SAR 2 million riyals per year, if IC was used
instead of MEM. This makes IC an attractive choice as a car-
bapenem in patients with moderate to severe infections.
Despite signiﬁcant differences in acquisition costs, laboratory
culture costs, pharmacist and pharmacy aide costs, the total
average costs per day was not signiﬁcantly different between
the 2 groups (SAR 4784.46 IC and SAR 4390.13 MEM,
p= 0.370).
It must be pointed out that some resource costs are unique
to the local perspective. These include resource costs that are
ﬁxed in the institution and not related to the number of patient
visits. Nursing services costs have daily rates rather than cost
per visit. IC requires more frequent administration and costs
were expected to be higher. However, with ﬁxed costs, this
was not apparent. Other costs such as consumables were also
ﬁxed. Most resources were variable and based on the number
of patient days or related to the frequency of administration.
A one-way sensitivity analysis showed that the mean total
costs were sensitive to hospital days, laboratory tests and con-
sultations charges. These ﬁndings did not support our
hypothesis that acquisition costs and costs related to
administration times play a major role in total daily costs.
Our study shows that costs related to the LOAS and
consultation charges may affect total costs much more than
acquisition costs or ADE costs.
A threshold analysis was performed on the hospital days,
acquisition costs and personnel costs. The only parameter
found to change the conclusion was CCU days. If the CCU
value was less than SAR 33.27, average total costs of IC would
be less costly than MEM. Our conclusion did not change for
the rest of the parameters even if the parameter value was
set to SAR 0.
This study was not without limitations. It was a retrospec-
tive single-cohort study that reﬂected the practices of a single
institution. Although a census approach over a calendar year
was used, the sample size was small.
Despite these limitations, our study has provided insight
into the factors inﬂuencing hospital budgets at our institution.7. Conclusions
This retrospective review found that although acquisition costs
for IC are signiﬁcantly less than those for MEM, the mean total
costs per day associated with these competing carbapenems
were not signiﬁcantly different. The results underlined the fact
that medicine acquisition costs are only a small component of
the overall costs of managing moderate to severe infections.
The study showed that those factors with the greatest impact
on hospital costs were related to the hospital stay, especially
Cost-minimization analysis of imipenem/cilastatin versus meropenem 633CCU days. Mean total costs were also sensitive to consultant
visits and laboratory cultures associated with CCU admission.
Nonetheless, this study supports the PTC recommendation of
carbapenem selection by restricting MEM to infection control
physician only. This position remains rational, and would
simplify procurement and clinical practice.
8. Notes
These data were previously presented in a Master of Pharmacy
mini-dissertation submitted to the University of KwaZulu–
Natal. They were also presented at the 5th King Abdullah
International Research Center Annual Scientiﬁc Forum in
2014.
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